1. Home
  2. DGII vs BEAM Comparison

DGII vs BEAM Comparison

Compare DGII & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$69.74

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$34.32

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGII
BEAM
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.0B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
DGII
BEAM
Price
$69.74
$34.32
Analyst Decision
Strong Buy
Buy
Analyst Count
5
12
Target Price
$48.80
$50.75
AVG Volume (30 Days)
291.8K
2.1M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
77.05
82.31
EPS
0.60
N/A
Revenue
$430,221,000.00
$24,000.00
Revenue This Year
$18.71
N/A
Revenue Next Year
$7.22
$33.77
P/E Ratio
$115.28
N/A
Revenue Growth
1.46
33.33
52 Week Low
$30.69
$15.60
52 Week High
$70.82
$36.88

Technical Indicators

Market Signals
Indicator
DGII
BEAM
Relative Strength Index (RSI) 58.37 59.75
Support Level $61.79 $26.96
Resistance Level $70.30 $36.44
Average True Range (ATR) 2.68 2.18
MACD -0.24 0.34
Stochastic Oscillator 80.19 68.09

Price Performance

Historical Comparison
DGII
BEAM

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: